These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

397 related articles for article (PubMed ID: 31527453)

  • 1. Synergistic Cytotoxicity of Renieramycin M and Doxorubicin in MCF-7 Breast Cancer Cells.
    Tun JO; Salvador-Reyes LA; Velarde MC; Saito N; Suwanborirux K; Concepcion GP
    Mar Drugs; 2019 Sep; 17(9):. PubMed ID: 31527453
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting P-glycoprotein function, p53 and energy metabolism: Combination of metformin and 2-deoxyglucose reverses the multidrug resistance of MCF-7/Dox cells to doxorubicin.
    Xue C; Wang C; Sun Y; Meng Q; Liu Z; Huo X; Sun P; Sun H; Ma X; Ma X; Peng J; Liu K
    Oncotarget; 2017 Jan; 8(5):8622-8632. PubMed ID: 28052008
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transcriptomic insight into salinomycin mechanisms in breast cancer cell lines: synergistic effects with dasatinib and induction of estrogen receptor β.
    Bellat V; Verchère A; Ashe SA; Law B
    BMC Cancer; 2020 Jul; 20(1):661. PubMed ID: 32678032
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of resveratrol on doxorubicin resistance in breast neoplasm cells by modulating PI3K/Akt signaling pathway.
    Chen JM; Bai JY; Yang KX
    IUBMB Life; 2018 Jun; 70(6):491-500. PubMed ID: 29637742
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Liposomes co-encapsulating doxorubicin and glucoevatromonoside derivative induce synergic cytotoxic response against breast cancer cell lines.
    Novais MVM; Gomes ER; Miranda MC; Silva JO; Gomes DA; Braga FC; Pádua RM; Oliveira MC
    Biomed Pharmacother; 2021 Apr; 136():111123. PubMed ID: 33486211
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination treatment of ligustrazine piperazine derivate DLJ14 and adriamycin inhibits progression of resistant breast cancer through inhibition of the EGFR/PI3K/Akt survival pathway and induction of apoptosis.
    Chen J; Wang W; Wang H; Liu X; Guo X
    Drug Discov Ther; 2014 Feb; 8(1):33-41. PubMed ID: 24647156
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aldo-keto reductase 1C3 (AKR1C3) is associated with the doxorubicin resistance in human breast cancer via PTEN loss.
    Zhong T; Xu F; Xu J; Liu L; Chen Y
    Biomed Pharmacother; 2015 Feb; 69():317-25. PubMed ID: 25661377
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oleuropein inhibits migration ability through suppression of epithelial-mesenchymal transition and synergistically enhances doxorubicin-mediated apoptosis in MCF-7 cells.
    Choupani J; Alivand MR; M Derakhshan S; Zaeifizadeh M; S Khaniani M
    J Cell Physiol; 2019 Jun; 234(6):9093-9104. PubMed ID: 30317622
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Apoptosis Inducing Activity of Rhinacanthin-C in Doxorubicin-Resistant Breast Cancer MCF-7 Cells.
    Chaisit S; Jianmongkol S
    Biol Pharm Bull; 2021; 44(9):1239-1246. PubMed ID: 34471052
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The carotenoid fucoxanthin can sensitize multidrug resistant cancer cells to doxorubicin via induction of apoptosis, inhibition of multidrug resistance proteins and metabolic enzymes.
    Eid SY; Althubiti MA; Abdallah ME; Wink M; El-Readi MZ
    Phytomedicine; 2020 Oct; 77():153280. PubMed ID: 32712543
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Resveratrol enhances chemosensitivity of doxorubicin in multidrug-resistant human breast cancer cells via increased cellular influx of doxorubicin.
    Kim TH; Shin YJ; Won AJ; Lee BM; Choi WS; Jung JH; Chung HY; Kim HS
    Biochim Biophys Acta; 2014 Jan; 1840(1):615-25. PubMed ID: 24161697
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synergistic breast cancer suppression efficacy of doxorubicin by combination with glycyrrhetinic acid as an angiogenesis inhibitor.
    Shi J; Li J; Li J; Li R; Wu X; Gao F; Zou L; Mak WWS; Fu C; Zhang J; Leung GP
    Phytomedicine; 2021 Jan; 81():153408. PubMed ID: 33234363
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Highly synergistic effect of sequential treatment with epigenetic and anticancer drugs to overcome drug resistance in breast cancer cells is mediated via activation of p21 gene expression leading to G2/M cycle arrest.
    Vijayaraghavalu S; Dermawan JK; Cheriyath V; Labhasetwar V
    Mol Pharm; 2013 Jan; 10(1):337-52. PubMed ID: 23215027
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A critical dose of doxorubicin is required to alter the gene expression profiles in MCF-7 cells acquiring multidrug resistance.
    Tsou SH; Chen TM; Hsiao HT; Chen YH
    PLoS One; 2015; 10(1):e0116747. PubMed ID: 25635866
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Apoptosis-inducing Effect of Hydroquinone 5-
    Maiuthed A; Pinkhien T; Chamni S; Suwanborirux K; Saito N; Petpiroon N; Chanvorachote P
    Anticancer Res; 2017 Nov; 37(11):6259-6267. PubMed ID: 29061809
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Schisandrin A reverses doxorubicin-resistant human breast cancer cell line by the inhibition of P65 and Stat3 phosphorylation.
    Zhang ZL; Jiang QC; Wang SR
    Breast Cancer; 2018 Mar; 25(2):233-242. PubMed ID: 29181822
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Altered expression of proliferation-inducing and proliferation-inhibiting genes might contribute to acquired doxorubicin resistance in breast cancer cells.
    Saleh EM; El-Awady RA; Abdel Alim MA; Abdel Wahab AH
    Cell Biochem Biophys; 2009; 55(2):95-105. PubMed ID: 19593673
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epigenetic immunomodulatory effect of eugenol and astaxanthin on doxorubicin cytotoxicity in hormonal positive breast Cancer cells.
    Fouad MA; Sayed-Ahmed MM; Huwait EA; Hafez HF; Osman AM
    BMC Pharmacol Toxicol; 2021 Jan; 22(1):8. PubMed ID: 33509300
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Selective targeting of FAK-Pyk2 axis by alpha-naphthoflavone abrogates doxorubicin resistance in breast cancer cells.
    Datta A; Bhasin N; Kim H; Ranjan M; Rider B; Abd Elmageed ZY; Mondal D; Agrawal KC; Abdel-Mageed AB
    Cancer Lett; 2015 Jun; 362(1):25-35. PubMed ID: 25796439
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A novel doxorubicin-mitomycin C co-encapsulated nanoparticle formulation exhibits anti-cancer synergy in multidrug resistant human breast cancer cells.
    Shuhendler AJ; Cheung RY; Manias J; Connor A; Rauth AM; Wu XY
    Breast Cancer Res Treat; 2010 Jan; 119(2):255-69. PubMed ID: 19221875
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.